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6E11, a highly selective inhibitor 
of Receptor-Interacting Protein 
Kinase 1, protects cells against cold 
hypoxia-reoxygenation injury
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M. Hauteville13, P. G. Goekjian14, R. Thuillier6,7,8,9,10, F. Favreau6,7,8,9,10, P. Vandenabeele  4,15, 
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Necroptosis is a programmed cell death pathway that has been shown to be of central 
pathophysiological relevance in multiple disorders (hepatitis, brain and cardiac ischemia, pancreatitis, 
viral infection and inflammatory diseases). Necroptosis is driven by two serine threonine kinases, RIPK1 
(Receptor Interacting Protein Kinase 1) and RIPK3, and a pseudo-kinase MLKL (Mixed Lineage Kinase 
domain-Like) associated in a multi-protein complex called necrosome. In order to find new inhibitors 
for use in human therapy, a chemical library containing highly diverse chemical structures was screened 
using a cell-based assay. The compound 6E11, a natural product derivative, was characterized as a 
positive hit. Interestingly, this flavanone compound: inhibits necroptosis induced by death receptors 
ligands TNF-α (Tumor Necrosis Factor) or TRAIL (TNF-Related Apoptosis-Inducing Ligand); is an 
extremely selective inhibitor, among kinases, of human RIPK1 enzymatic activity with a nM Kd; has 
a non-ATP competitive mode of action and a novel putative binding site; is weakly cytotoxic towards 
human primary blood leukocytes or retinal pigment epithelial cells at effective concentrations; protects 
human aortic endothelial cells (HAEC) from cold hypoxia/reoxygenation injury more effectively than 
necrostatin-1 (Nec-1) and Nec-1s. Altogether, these data demonstrate that 6E11 is a novel potent small 
molecular inhibitor of RIPK1-driven necroptosis.
Programmed cell death (PCD) is a natural process for removing unwanted cells in both pathological and 
non-pathological contexts. Cell death has long been dominated by apoptosis, but include now a growing list of 
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regulated necrosis pathways, including necroptosis, ferroptosis, parthanatos or cyclophilin D (CypD)-dependent 
necrosis (see1 for review). Necroptosis is so far the best-studied form of non-apoptotic cell death. This peculiar 
PCD does not involve key apoptosis regulators, such as caspases, Bcl-2 family members or cytochrome c release 
from mitochondria. A series of small chemical inhibitors (termed necrostatins) was used to characterize the Ser/
Thr RIPK1 (Receptor-Interacting Protein Kinase 1) kinase as key regulator of necroptosis2,3.
Necroptosis is activated upon stimulation of death receptors by the cytokines TNF-α (Tumor Necrosis Factor 
α), FasL (Fas Ligand) and TRAIL (Tumor-necrosis-factor Related Apoptosis-Inducing Ligand) when caspase-8 
is inhibited or absent. The TNFR1 (Tumor Necrosis Factor Receptor 1)-mediated necroptosis is known as the 
prototype of regulated necrosis. The binding of TNF to its receptor TNFR1 leads to the formation of a sequence of 
signaling complexes finely tuned by ubiquitylation and deubiquitylation events. The receptor-associated “complex 
I” induces prosurvival signals through activation of NF-κB (Nuclear Factor – kappa B) and MAPKs (Mitogen 
Activated Protein Kinases), while other cytosolic complexes drive two different programmed cell deaths: (i) 
apoptosis, via formation of complex including FADD (Fas-Associated Death Domain) that recruits caspase-8 
to activate a caspase-dependent cascade; or (ii) necroptosis, via activation of RIPK1 and two other key players, 
Ser/Thr RIPK3 kinase and the pseudokinase MLKL (Mixed Lineage Kinase Domain-Like) in a complex called 
the “necrosome”4. In accordance with this activation cascade, TNF-α was shown to induce necroptosis in human 
Jurkat T cells when FADD is deleted5.
The ground-breaking finding that necroptosis is a genetically controlled process led to the hypothesis that 
this programmed cell-death is ‘druggable’, an emerging breakthrough that carries the potential for significant 
advances in everyday clinical medicine2. Indeed molecular targets, including RIPK1, RIPK3 and MLKL, have 
been shown to be involved in multiple disease models where necroptosis is of central pathophysiological rele-
vance, such as: in ischemia-reperfusion injury (including stroke, myocardial infarction, resuscitation, solid organ 
transplantation or heart surgery) in brain, heart and kidney diseases, and in inflammatory diseases, including 
moderate to severe Rheumatoid Arthritis (RA), psoriasis, retinal disorders, neurodegenerative diseases and infec-
tious disorders (sepsis, viral infections, parasites, bacterial infections)6,7 (Fig. 1). More recently, it has been shown 
that human and murine tumor cells induce necroptosis of endothelial cells, which promotes tumor cell extrava-
sation and metastasis8. Necroptosis can thus also be targeted in the treatment of human metastasis, the leading 
cause of cancer-related death in humans.
Following the molecular description of necroptosis and the characterization of necrostatins2,3,9, various screen-
ing initiatives using cell-based assays or high-throughput in vitro RIPK1 binding assays have shed light on new 
chemical scaffolds including the 1-aminoisoquinolines10, 5-phenylpyrrolo[2,3-b]pyridines10, 5-arylpyrrolo[2,3-b]
pyridines10, furo[2,3-d]pyrimidines10, analogs of Bcr-Abl inhibitor ponatinib11,12, PN10 (hybrid of ponatinib and 
Nec-1s)11, the benzo[b][1,4]oxazepin-4-ones13, the compound GSK’96314 and the RIPA-5615. The quest for an 
optimized clinical candidate is still in progress with the synthesis of the first-in-class RIPK1 specific inhibitor 
(GSK2982772)16.
We now reported here the selection of a new highly selective inhibitor of RIPK1, 2-(4-(benzyloxy)phenyl)-2,5
-dihydroxy-7-methoxychroman-4-one (compound called 6E11), using a phenotypic cell screen which detects the 
ability of small chemicals to block TNF-driven necrotic death. Moreover, we show that this new inhibitor protects 
cells from cold hypoxia/reoxygenation injury. This work sheds light on the interest to study natural products or 
derivatives in the quest of drugs targeting necroptosis-related disorders.
Figure 1. Impact of RIPK1-dependent necroptosis in human diseases. The comprehensive list of the references 
can be found as Supplementary Table S1.
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Results
Discovery of a novel potent small molecular inhibitor of necroptosis. To identify new necroptosis 
inhibitors, a robust TNF-induced FADD-deficient human Jurkat necroptosis assay was used to screen a chemi-
cal library of 2,800 compounds belonging to the chemical library of University Claude Bernard (ICBMS, Lyon, 
France) (Fig. 2a). The screening process was assessed using a viability test based on cell proliferation measure-
ment (MTS). Among the tested molecules, compound 6E11 was found to be the more potent to block the TNF-
induced necrotic cell death with an EC50 of 4.6 μM. Although less potent than Nec-1s (EC50 of 0.1 μM), 6E11 is a 
novel core for structural optimization (Fig. 2b). Its inactive analogue 8A03 did not show any inhibition towards 
necrotic cell death. The chemical structures of these compounds are depicted on Fig. 2a. 6E11 is a natural product 
derivative as it’s a synthetic derivative of the naturally occuring 2,5-dihydroxy-2-phenylchroman-4-ones isolated 
from Populus nigra buds17. The bioactivity of 6E11 was studied in the work reported here.
6E11 is selective towards death receptor-induced necroptosis. 6E11’s ability to inhibit necroptosis 
was compared to Nec-1 in human cell lines in vitro. This antinecroptotic activity of 6E11 was demonstrated by 
measurements of intracellular adenosine triphosphate (ATP) levels (Fig. 3a), plasma membrane permeabiliza-
tion (% of propidium iodide positive cells) (Fig. 3b) and mitochondrial transmembrane potential in living cells 
(DiOC6(3) measurement) (Fig. 3c). Necroptosis was induced by necroptotic triggers such as TNF-α in human 
FADD-deficient Jurkat T cells resistant to extrinsic apoptosis (Fig. 3a–c) or TRAIL + Z-VAD + CHX in human 
WT Jurkat T cells (Fig. 3d). In both models, 6E11 blocked necroptosis in a dose-dependent manner (Fig. 3a–d). 
Figure 2. Characterization of hit compound 6E11 as new necroptosis inhibitor. (a) Workflow of the cell-
based screening of ICBMS chemical library for the selection of new inhibitors of necroptosis. Among 2,800 
compounds, 6E11, was selected as the more potent inhibitor of TNF-α-induced necroptosis in human FADD-
deficient Jurkat T cells. The chemical structures of 6E11 and its negative control (8A03) are depicted above the 
workflow. The primary screening is performed in monoplicate. The negative control was not detected during the 
screening campaign. (b) Dose-dependent protection of 6E11 against TNF-α-induced Jurkat FADD deficient cell 
necroptosis. After a 24-h incubation of the cells with or without (w/o) TNF-α and increasing concentrations of 
tested compounds, the effect on the cell viability was evaluated by MTS reduction assay. The cells were treated 
only with the tested compound to evaluate its putative toxicity. The values were normalized as a percentage of 
cell viability, considering 100% viable cells in the control treated with DMSO (n = 3, mean ± SD).
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Moreover, as Nec-1, 6E11 did not rescue WT Jurkat cells from apoptosis induced by TRAIL (Fig. 3e). We shown 
also that 6E11 did not protect murine cell lines (L929 or MEFs) from necroptotic stimulus (see Supplementary 
Fig. S1 describing the data obtained on L929 cells). These results indicate that 6E11 blocks necroptotic but not 
apoptotic cell death and suggest that this anti-necroptotic efficacy is species-specific.
6E11 is not cytotoxic at inhibitory concentrations and rescues cells from necroptosis even 
after necrotic stimulus induction. 6E11 has a little or no cytotoxic effect in the range of 1 to 25 µM 
against human peripheral blood leukocytes (PBL) or human retinal pigment epithelial cells (RPE-1 hTERT) 
(Fig. 4a), concentrations at which it significantly suppresses necroptosis. In order to investigate 6E11 activity 
Figure 3. 6E11 inhibits death receptor-induced necroptosis, but not apoptosis. (a) Human FADD-deficient 
Jurkat T cells were treated or not with TNF-α (10 ng/ml) in presence or not of increasing concentrations of 
6E11 (0, 1, 5, 10 µM) or Nec-1 (0, 5, 10 µM) for 18 hours. Intracellular ATP levels were measured with the 
CellTiter-Glo® Luminescent Cell Viability Assay (n = 3, mean ± SEM, *P < 0.05) (EC50 ~6 µM). (b) Human 
FADD-deficient Jurkat T cells were treated or not with TNF-α (10 ng/ml) in presence or not of increasing 
concentrations of 6E11 (0, 5, 10, 20 µM) or Nec-1 (0, 5, 10 µM) for 18 hours. The percentage of cell death 
was determined by propidium iodide staining using flow cytometry (n = 3, mean ± SEM, **P < 0.01 and 
***P < 0.001). (c) Human FADD-deficient Jurkat T cells were treated or not with TNF-α (10 ng/ml) in presence 
or not of increasing concentrations of 6E11 (0, 5, 10, 20 µM) for 18 hours. The mitochondrial transmembrane 
potential (MTP) was measured using the fluorescent dye DiOC6(3) and flow cytometry analysis. (d) 6E11 
inhibits TRAIL-induced necroptosis. Wild-type Jurkat T cells were treated or not with TRAIL (10 ng/ml), 
Z-VAD (30 µM) and CHX (1 µg/ml) for 18 hours in presence or not of increasing concentrations of 6E11 (0, 5, 
10, 20 µM) or 10 µM Nec-1. The percentage of cell death was determined by propidium iodide staining using 
flow cytometry (n = 3, mean ± SEM, **P < 0.01). (e) 6E11 does not inhibit TRAIL-induced apoptosis. Wild-
type Jurkat T cells were treated or not with TRAIL (20 ng/ml) for 18 hours in presence or not of increasing 
concentrations of 6E11 (0, 5, 10, 20 µM) or Nec-1 (0, 5, 10, 20 µM). The percentage of cell death was determined 
by propidium iodide staining using flow cytometry (n = 3, mean ± SEM).
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as a necroptosis inhibitor in a potentially relevant clinical scenario, we investigated its efficacy after, rather than 
before, necroptosis induction. 6E11 was added at a concentration of 10 µM from 1 h to 4 h after TNF treatment in 
FADD-deficient Jurkat cells. When added from one to four hours following necroptosis induction, 6E11 rescues 
FADD-deficient Jurkat cells from 60% cell death to approximately 20% (Fig. 4b).
6E11 is a highly selective inhibitor of human RIPK1 among protein kinases. To elucidate the 
binding mode of 6E11 and to identify its target, the selectivity of 6E11 was assessed at 10 µM against a panel of 
456 kinases (mainly human) in an in vitro competition binding assay (KINOMEscan®, DiscoverX, San Diego, 
CA, USA). 6E11 showed an almost absolute kinase selectivity towards human RIPK1. Only Mek5 was shown to 
be poorly affected by 6E11 (see Supplementary Table S2 for details). In these results, 6E11 competes with 99.85% 
of RIPK1-ligand complexes leading to prevention of kinase binding to the immobilized ligand (Supplementary 
Table S2 and blue circle on Fig. 5a). The dissociation constant (Kd) of 6E11 for RIPK1 was calculated with a stand-
ard dose-response curve using this competition-binding assay. 6E11 shows a high affinity for RIPK1 with a Kd of 
130 nM (Fig. 5b, left and right panels). High affinity Nec-1s for RIPK1 was also confirmed with Kd equal to 26 nM 
(at room temperature). Contrarily to Nec-1s, the binding affinity of 6E11 to RIPK1 is sensitive to the temperature. 
The affinity of 6E11 for RIPK1 is higher at 4 °C and room temperature than at 37 °C (Fig. 5b, right panel).
To monitor RIPK1 enzymatic activity in presence of 6E11, we performed an in vitro auto-phosphorylation 
assay using recombinant full-length RIPK1 (GST-tagged). This assay showed an inhibition of RIPK1 
auto-phosphorylation by 6E11 in a dose-dependent manner (Fig. 6a). The enzymatic activity of RIPK1 was also 
quantified by monitoring the phosphorylation of Myelin-Basic Protein (MBP), a known substrate of RIPK1. 
Accordingly, 6E11 efficiently inhibited the phosphorylation of MBP in a dose-dependent manner with an IC50 
equal to 1.2 µM with 20 µM ATP (Fig. 6b). To further characterize the mechanism of RIPK1 inhibition by 6E11, 
we monitored RIPK1 activity in the presence of 6E11, with increasing concentrations of cold ATP (up to 1 mM). 
Figure 4. 6E11 is not cytotoxic at inhibitory concentration and protects from necroptosis even after cell death 
initiation. (a) 24 hours after treatment with increasing concentrations of 6E11, cell viability was measured 
with a MTS assay to determine the toxicity of the compound towards either human PBL (upper panel) (n = 6 
individuals, mean ± SEM) or human retina pigmented epithelial cells (RPE-1 hTERT) (lower panel) (n = 3, 
mean ± SD). (b) Viability was measured with a MTS assay in FADD-def Jurkat cells treated with TNF-α (10 ng/
ml) followed by 10 µM 6E11 addition 1 to 4 h post necroptosis initiation (n = 4, mean ± SEM, *P < 0.05;  
**P < 0.01).
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Results obtained show that, in the presence of increasing concentrations of ATP, the inhibitory activity of 6E11 on 
RIPK1 auto-phosphorylation was maintained. 6E11 is thus a non-ATP competitor (Fig. 6b). Nec-1 was described 
as an ATP competitive compound3. Very interestingly, 6E11 had no significant effect at 10 µM on RIPK3 kinase 
activity (Fig. 6c). Taken altogether, these data demonstrated that 6E11 is a specific inhibitor of RIPK1 kinase 
activity acting through a different inhibition mechanism than Nec-1.
6E11 has a putative binding site out of the ATP binding cleft of RIPK1. The predictive orientation 
for the hit compound described here was studied by in silico analysis of the theoretical RIPK1-6E11 complex. 
Stable contact residues defining a pharmacophore and determined on the most representative structural model 
included six key amino acids Lys30, Val47, Leu60, Leu78, Tyr88 and Leu90 (Fig. 7a). Surrounding residues (4.0 Å 
cut-off distance) describing the 6E11 binding pocket observed over the molecular docking simulation trajectory 
also comprised of Phe28, Val31, Lys45, Thr46, Ala59, Glu63, Val81, Ile83, Ser89 and Asp156. We should note that 
among these amino acids, three of them (Leu78, Leu90 and Asp156) have been already described to be involved 
in the interaction with necrostatins (see18 for details on RIPK1-Necrostatins complexes) (Fig. 7a). Molecular 
dynamic (MD) simulation of RIPK1-6E11 model allowed us to improve the preferential binding mode identified 
by docking calculations which is different from Nec-1s (Fig. 7b,c). The binding site #1 of Nec-1s is marked with a 
orange circle on Fig. 7b. From analysis of the most frequent contacts of the compound to the kinase, we are able to 
propose that 6E11 should bind RIPK1 kinase through tight hydrophobic interactions and a non-specific hydrogen 
bond (HB), as well as other transient HB interactions observed during the simulation (Fig. 7b,c). The putative 
Figure 5. 6E11 is a highly selective inhibitor of human kinase RIPK1. (a) Selectivity of 6E11 was assessed 
biochemically against a panel of 456 purified kinases (KINOMEscanSM Assay) at 10 µM and the compound was 
found to be highly selective for RIPK1. Only 0.15% of the initial amount of RIPK1 is still on the affinity matrix 
after competition with 6E11 (the full list of results is reported in Supplementary Table S2). S-Score35 = (number 
of non-mutant kinases with %Ctrl < 35)/(number of non-mutant kinases tested). (b) Measure of the binding 
constant for RIPK1/6E11 and RIPK1/Nec-1s interactions. Two 11-point 3-fold serial dilutions of 6E11 and 
Nec-1s were prepared in 100% DMSO in order to determine the binding constant (Kd). Kds are calculated at 
three various temperatures by measuring the amount of kinase captured on the solid support as a function of 
the test compound concentration (n = 2, mean ± range).
www.nature.com/scientificreports/
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binding site #2 of 6E11 is marked with a blue circle on Fig. 7b. Our simulations suggest that 6E11 fits tightly in an 
alternative and putative cleft surrounded notably by the RIPK1 catalytic triad residues: Lys45, Glu63 and Asp156. 
This cleft of RIPK1 is mainly hydrophobic but richer in hydrogen bond acceptors than the kinase hinge within the 
ATP-binding site. Interestingly, this model shows that 6E11 does not make any interaction with the kinase hinge 
Figure 6. 6E11 inhibits the enzymatic activity of RIPK1 with a non-ATP competitive mode of action. (a) RIPK1 
was treated with 5, 10 or 50 µM of 6E11 to analyze the effect on the kinase autophosphorylation. Radioactive 
autophosphorylation assays were processed with [γ-32P] ATP at 30 µM final concentration. Necrostatin-1 
(Nec-1) was used as an internal control. Coomassie blue staining was performed in order to estimate the 
total amount of protein loaded on polyacrylamide gel. Autophosphorylated RIPK1 band was visualized on 
radiographic film. % of RIPK1 activity inhibition are calculated through a ratio with DMSO, as a 0 percent 
reference. See Supplementary Fig. S2 for results of the full-length gel obtained at various exposure times. (b) 
ATP competition assay shows that inhibition of RIPK1 activity by 6E11 is not affected by ATP concentration. 
On the left panel, 0.25 or 1 mM of cold ATP were used to study the competition with 6E11. These assays are 
similar to those described in (a). The phosphorylation signal is modified by increasing doses of ATP due to the 
dilution of [γ-32P] ATP by “cold” non radiolabeled ATP. % of RIPK1 activity inhibition are calculated for each 
ATP concentration through a ratio with DMSO (-), as a 0 percent reference. See Supplementary Fig. S2 for 
results of the full-length gel. The RIPK1 catalytic activity was also monitored using myelin basic protein, MBP, 
as a substrate (right panel). GST-RIPK1 full length produced by baculovirus in Sf9 insect cells was assayed in 
the presence of increasing concentrations of 6E11. The kinase activities are expressed in % of maximal activity, 
i.e. measured in the absence of inhibitor. The IC50 values obtained at various ATP concentrations are reported 
in the table (n = 3, mean ± SD). (c) 6E11 is inactive on RIPK3 activity. GST-RIPK3 full length produced by 
baculovirus in Sf9 insect cells was assayed in the presence of 10 µM of inhibitor with [γ-33P] ATP and myelin 
basic protein, MBP, as a substrate. GSK’872 was used as RIPK3 reference inhibitor. Kinase activities are 
expressed in % of maximal activity, i.e. measured in the presence of DMSO (as a 100% reference).
www.nature.com/scientificreports/
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in this conformation of RIPK1 regardless of hydrogen bonds. Moreover, this proposed binding mode for 6E11 
occupying a lipophilic pocket in a cleft near the substrate binding site of RIPK1 indicates that this compound is 
likely a type III kinase inhibitor. This binding mode is in line with the high selectivity of 6E11 detected by the 
KINOMEscanSM Assay (Fig. 5a) and also with the non-ATP competitive mode of inhibition (reported on Fig. 6b).
6E11 protects human aortic endothelial cells (HAEC) from cold hypoxia-reoxygenation. 
Hypoxic cold storage condition mimics the situation occurring during ex vivo graft preservation and the cold 
hypoxia/reoxygenation sequence mimics organ transplantation process, two situations in which necrotic cell 
death occurs. HAEC cells were washed in PBS then incubated with University of Wisconsin (UW) preservation 
solution in anoxic and hypoxic conditions for 24 h (simulating cold ischemia organ preservation), after which the 
medium was changed and cells put in regular culture conditions (simulating reperfusion). To assess the potential 
protective activity of our compounds against cold ischemia, increasing concentrations of 6E11, Nec-1, Nec-1s, 
or 8A03 were added to the UW for the preservation steps. The compounds were added at various steps of the 
hypoxia reoxygenation sequence (see Supplementary Fig. S3 for a detailed view of the experiment). The treat-
ment with compound 6E11 during cold hypoxia or during cold hypoxia and reoxygenation brought measurable 
benefits on cell survival. Compared to the control inhibitors of necroptosis (Nec-1 and Nec-1s), the effect of com-
pound 6E11 was significantly better (Fig. 8a and b). No protective effect was observed when 6E11 was added only 
at the reoxygenation step (Fig. 8c). The structurally related compound 8A03 was shown to be inactive.
Discussion
Nearly 50% of all approved drugs from the 1940s to 2014 are of natural origin19, actually being either natural 
products or directly derived therefrom. This percentage highlights the crucial impact of studies of natural prod-
ucts on the discovery of new drugs. In line with this observation, the present study reports the characterization 
of a novel highly selective natural product derivative inhibitor of RIPK1. By using a cell-based screening assay to 
analyze a French academic chemical collection of 2800 small molecular compounds, we identified 6E11 as a new 
inhibitor of programmed necrosis with a micromolar EC50 concentration. 6E11, 2-(4-(benzyloxy)phenyl)-2,5-
dihydroxy-7-methoxychroman-4-one, is a compound derived from the 2,5-dihydroxy-2-phenylchroman-4-ones 
isolated from Populus nigra buds17. This study enlarges the chemical families of potent necroptosis inhibitors. 
6E11 was shown to inhibit TNF-α or TRAIL-induced necroptosis in human Jurkat cells but not TRAIL-induced 
apoptosis. In both models, 6E11 inhibited hallmarks of necroptosis in a dose-dependent manner, notably the 
plasma membrane permeabilization and the decrease of intracellular ATP levels. In order to study the mecha-
nism of action of 6E11, a KINOMEscan® was performed and showed that RIPK1 was specifically affected by the 
selected chemical compound with a low nanomolar Kd (130 nM at room temperature). Mek5 was the only other 
kinase weakly affected among the large set tested (456 kinases, wild type and mutants). In line with this result, 
Figure 7. Molecular model of the RIPK1-6E11 complex. (a) Close-up view of the putative interaction between 
6E11 and surrounding residues in RIPK1 extracted from the best pose of docking simulation improved by 
60 ns molecular dynamic trajectory (key-residues are shown in italic and bold, residues common to Nec-1s and 
6E11 binding sites are in red). Asp156, one of the RIPK1 catalytic triad residues, but more slightly contacting 
6E11, is shown in orange spheres to complete the description of the close environment of the ligand. (b) Overall 
structure of RIPK1 showing the putative binding site of 6E11 highlighted in blue dashed circle (site #2). The 
binding site (site #1) of Nec-1s (determined from the X-ray structure 4ITH) is marked with a orange dashed 
circle on the same panel. (c) Relative positions and orientations of each 6E11 and Nec-1s compounds shown in 
a close-up view.
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Figure 8. 6E11 protects HAEC from cold hypoxia reoxygenation injury when treatment occurs during cold 
hypoxia step (a), during both cold hypoxia and reoxygenation steps (b), but not when treatment occurs during 
the reoxygenation step (c). Increasing concentrations (1, 3.33, 10, 33.3 µM) of 6E11, Nec-1, Nec-1s or 8A03 were 
added to the UW preservation solution during hypoxia or/and in PBS – 2% FBS during reoxygenation. UW 
corresponds to cells treated with UW preservation solution. Controls are cells not subjected to this protocol and 
continuously oxygenated. DMSO are cells treated with drug vehicle. The ratio of cell viability evaluated by XTT 
test, is calculated in comparison to the untreated control (100% of cell viability). Data shown are mean ± SD, 
n = 3; ANOVA and Tukey’s Multiple Comparison Test; *P < 0.05 vs UW. See Supplementary Fig. S3 for a 
schematic representation of the protocol.
www.nature.com/scientificreports/
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we showed that RIPK3 kinase activity is not inhibited by 6E11 and that the inhibition of RIPK1 is not affected 
by high concentrations of ATP (up to 1 mM). Based on its high selectivity, on the non-ATP competitive mecha-
nism of inhibition, we hypothesized that 6E11 targets a pocket outside the ATP-binding cleft. The high sequence 
similarity in the ATP-binding site among members of the kinase families, a pocket targeted by the vast majority 
of kinase inhibitors discovered to date, often results in low selectivity and additional toxicities, and suffer from 
competition with high intracellular ATP concentrations. In order to predict a putative binding mode of 6E11 to 
the RIPK1 kinase domain we performed molecular simulations. The result obtained is shown on Fig. 7. In this 
model, 6E11 occupies a lipophilic pocket in the “back” cleft of RIPK1 and thus can be classified as type III kinase 
inhibitor (referred to as allosteric inhibitors) in a distinct site from Nec-1s. It interacts putatively with the three 
catalytic amino acids, Lys45, Glu63 and Asp156, in proximity to the triphosphate and substrate binding site. 
In contrast to Nec-1s, 6E11 does not compete with intracellular ATP (typically in the low-millimolar range) to 
negatively modulate RIPK1 activity. Interestingly, Degterev and Linkermann20 report in vivo studies showing 
that selective inhibition of RIPK1 should not be considered as the sole parameter in tackling deleterious effects of 
renal ischemia–reperfusion injury: Nec-1 is active whereas the more RIPK1-selective Nec-1s is not. In this study, 
we show that 6E11 has a stronger protective effect against cell death induced by cold hypoxia/ reoxygenation 
in HAEC than both Nec-1 and Nec-1s (Fig. 8). Ren et al.15 used a cell-based screen on a collection of 200,000 
compounds in order to identify another chemical scaffold of type III inhibitors, RIPA-56 (N-benzyl-N-hydroxy-
2,2-dimethylbutanamide), exhibiting an absolute selectivity for RIPK1. Harris et al.13 have characterized Benzo[b]
[1,4]-oxazepin-4-ones as type III mono-kinase selective RIPK1 inhibitors from a GSK’s property collection of 
DNA-encoded small-molecule libraries. Similarly to this class of RIPK1 inhibitors, we showed that 6E11 is also 
specific of human kinase. It will be very informative to test other type III inhibitors in the cold hypoxia/ reoxygen-
ation assay described here (see Supplementary Fig. S3). The concept of necroinflammation has recently emerged 
in ischemia/reperfusion injury. Necroinflammation can be initiated by a few necrotic cells that activate the innate 
immune system, which subsequently leads to necrosis of more cells triggering more inflammation in a process 
leading to organ failure. In this context, pharmacologic inhibition of regulated necrosis, if directly associated with 
inflammation, might functionally be considered as an anti-inflammatory treatment.
There are great clinical and basic research needs to characterize selective, high-affinity, small-molecule 
inhibitors of programmed necrosis-related kinases, including RIPK1. 6E11 is one of such compounds useful for 
pathway elucidation and target validation in addition to drug discovery. The RIPK1 inhibitor with this newly 
identified scaffold needs to be chemically optimized in order to study its potential use in clinic for improving the 
solid organ preservation and transplantation in conditions of static or dynamic cold ischemia. Our main objec-
tive is to increase the use of organs previously considered as marginal (e.g. from expanded criteria donors) in the 
context of the current organ shortage crisis. As mentioned on Fig. 1, necroptosis is implicated in a large spectrum 
of human disorders. Thus the bioactivity of such drug-like compound could also be investigated in other clinical 
use, such as psoriasis and ulcerative colitis.
Methods
Cell cultures. Jurkat wild-type A3, FADD-deficient Jurkat I 2.1 and RPE-1 hTERT human cell lines were 
obtained from ATCC (American Type Culture Collection, Rockville, MD, USA). Jurkat wild type, FADD-
deficient Jurkat cells were cultured in RPMI containing Glutamax (Invitrogen) supplemented with 15% FCS. 
RPE-1 hTERT cells were cultured in DMEM-F12 containing Glutamax (Invitrogen) supplemented with 10% FCS. 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient centrifugation from blood buffy 
coats of healthy donors, provided by the Etablissement Français du Sang (EFS). The research protocol was con-
ducted under French legal guidelines. After separation of monocytes by 1 h adhesion step, non-adherent PBMCs 
(PBL) were harvested. PBL were cultured in RPMI 1640 medium (Gibco, Life technologies, Carlsbad, CA, USA) 
supplemented with 10% decomplemented fetal calf serum (Life technologies), penicillin (100 IU/ml), and strep-
tomycin (100 µg/ml). All cells were cultured under a 5% CO2 atmosphere at 37 °C.
Reagents. Recombinant human Flag-tagged TRAIL (TRAIL-Flag) and z-VAD-fmk were obtained from 
Enzo Life Sciences (Villeurbanne, FR). Necrostatin-1 (Nec-1) and necrostatin-1s (Nec-1s) were from Calbiochem 
(VWR International, Fontenay-sous-Bois, FR). Anti-Flag M2 IgG1 antibody, cycloheximide (CHX), propidium 
iodide, were obtained from Sigma-Aldrich (St Quentin-Fallavier, FR). TNF-α was obtained from Invitrogen. This 
TNF was used in the screen of new necroptosis inhibitors. The chemical synthesis of 6E11 compound is described 
in Hauteville et al.21.
Cell-based screening assay for characterization of necroptosis inhibitors. The cell-based assay 
used in this study has been previously described by Miao and Degterev5. The protocol describing a screening cam-
paign is comprehensively reported in Le Cann et al.22. Briefly, necroptosis was induced in Jurkat FADD-deficient 
I 2.1 cell line by addition of 10 ng/ml of human recombinant TNF-α (Invitrogen). Necrostatin-1s (Nec-1s, 
7-Cl-O-Nec-1, Calbiochem) was used as positive necroptosis inhibitor. Chemical compounds collection plates 
were formatted at 10 mM in 100% DMSO in 96-well plates. For each collection plate, two 96-well clear, flat bot-
tom plates (CytoOne, Starlab) were seeded (at 20,000 cells/well) before treatment. One plate was treated with the 
tested compounds and TNF-α and the other plate was only treated with the tested compounds. Final concen-
tration of each chemical compound was 10 μM at 0,1% DMSO. Cells were incubated at 37 °C, 5% CO2 for 24 h 
before performing MTS viability assay according to the manufacturer’s instructions (CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay, Promega, Fitchburg, WI, USA). Compounds dilution and distribu-
tion in the plates were performed using the Nimbus Microlab liquid handler (Hamilton Robotics, Bonaduz, 
Switzerland) under microbiological safety workbench.
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Cell death assays. Cell viability was assessed by MTS assay, described here before. Cells were seeded at a 
density of 2.5 × 105 per well for human PBL or 8 × 103 cells per well for human RPE-1 hTERT cells in 96-well 
plates and then treated for 24 h. After the treatment, 20 μl of assay solution was added per well for 3 h incuba-
tion at 37 °C. The absorbance was determined by a microplate reader (SPECTROstar Nano, BMG Labtech) at 
490 nm and 630 nm. The percentage of viability were determined by subtracting the background reading (after 2 h 
incubation with blank medium) from the absorbance. Results were expressed through the following formula: % 
viability = (mean (OD490 − OD630) sample/mean (OD490 − OD630) control )× 100. Flow cytometry analyses were 
performed to detect necrotic cells using propidium iodide staining (500 ng/ml) from treated cell lines seeded at a 
density of 2.5 × 105 cells/well in 24-well plate.
Cell treatments. Necroptosis was induced by TNF-α or TRAIL treatment in different cellular models. 
FADD-deficient Jurkat cells were treated with 10 ng/ml human TNF-α for 18 h. Jurkat cells were pre-treated with 
Z-VAD-fmk (30 µM) and cycloheximide (1 µg/ml) for 30 min and then treated with TRAIL-Flag (200 ng/ml) 
and 2 µg /ml M2 anti-Flag antibody for 18 h. Apoptosis was induced in wild-type Jurkat cells by treatment with 
TRAIL-Flag (20 ng/ml) and 2 µg/ml M2 anti-Flag antibody for 18 h. The percentage of propidium iodide positive 
cells was measured by flow cytometry analysis of fluorescence (FL-2) (FACScalibur, Becton Dickinson, Le Pont 
de Claix, FR) and expressed as %/NT.
Cellular ATP concentration measurement. FADD-deficient Jurkat cells were seeded for 24 h at a density 
of 2 × 104 cells/well in white 96-well plate and then treated with human TNF-α (10 ng/ml). ATP concentration 
was measured using CellTiter-Glo® Luminescent Cell viability assay kit (Promega) according to the manufactur-
er’s instruction. ATP concentration was expressed as %/NT ± SD.
RIPK1 and RIPK3 kinase assays. Human RIPK1 full length GST-tagged was purchased from SignalChem 
(Richmond, CA, USA). The protocol used to detect the enzymatic activity was adapted from Degterev et al.3. 
RIPK1 autophosphorylation was assessed by mixing 5 μl of RIPK1, 5 μl of 3X kinase reaction buffer (5 mM MOPS 
pH 7.2, 2.5 mM β-glycerophosphate, 4 mM MgCl2, 2.5 mM MnCl2, 1 mM EGTA, 0.4 mM EDTA, 50 μg/ml BSA, 
0.05 mM DTT), 2 μl H2O and 3 μl of the tested molecule. This “RIPK1 reaction mix” was incubated on ice for 
10 min. During this time, the ATP solution was prepared by mixing 5 μl of 3X kinase reaction buffer, 4 μl H2O, 6 μl 
cold ATP at 150 μM and 2 μCi of [γ-32P] ATP. This ATP solution and the RIPK1 reaction mix were then mixed 
and incubated for 30 min at 30 °C. 25 μl of each reaction were loaded in pre-cast NuPage 12% Bis-Tris gel (Thermo 
Fisher Scientific) and analyzed by SDS-PAGE. Autophosphorylated RIPK1 band was visualized by analysis in a 
Typhoon Phosphorimager (GE Healthcare Life Sciences, Velizy-Villacoublay, France). Alternatively, the kinase 
activity of RIPK1 can be detected using “P81 phosphocellulose assay”. Briefly, 2 µl of kinase was assayed in buffer 
described above with 0.1 µg/µl of myelin basic protein (MBP, Sigma, #M1891) as substrate and in the presence of 
15 µM [γ-33P] ATP (3,000 Ci/mmol; 10 mCi/ml). After 30 min incubation at 30 °C, the reaction mix was spotted 
onto 81mm × 115mm sheets of P81 ion exchange cellulose chromatography paper (Product #IEP-01, Reaction 
Biology Corp., Malvern, PA, USA) using a FilterMate Harvester (PerkinElmer, Waltham, MA, USA) to remove 
residual [γ-33P] ATP. After extensive washes with a 1% solution of phosphoric acid using a FilterMate Harvester 
(PerkinElmer, Waltham, MA, USA), the wet filters were counted in the presence of 20 µl ACS (GE Healthcare) 
scintillation fluid using a TopCount® Scintillation and Luminescence Counter (PerkinElmer, Waltham, MA, 
USA). Maximal kinase activity was assessed with appropriate dilutions of DMSO. The kinase activity of RIPK3 
(human, recombinant, expressed by baculovirus in Sf9 insect cells) was detected with 0.1 µg/µl of MBP as sub-
strate following the assay described above.
Kinase binding assays. Competition binding assays were performed by DiscoverX (Freemont, CA, USA). 
Details about these assays can be found in Fabian et al.23 and Karaman et al.24 and on the Discoverx website 
[http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan]. In 
this study, binding assays were used for (i) the analysis of selectivity against a large panel of kinases (service 
“KINOMEscan®”) and for (ii) the determination of binding constant (Kd) of small chemical compound for 
RIPK1 (service “KdELECT”).
Mitochondrial transmembrane potential (MTP) assay. Mitochondrial transmembrane potential 
(MTP) was measured using 3,3′-dihexyloxacarbocyanine iodide, DiOC6(3), and flow cytometry analysis. Human 
FADD-deficient Jurkat cells were incubated with 6E11 at various concentrations and TNF-α (10 ng/ml) for 18 h. 
Then treated cells were incubated with DiOC6(3) at 50 nM (the final concentration) for 20 min and investigated 
for the reduction of MTP by using flow cytometry.
Molecular docking. According to our previous work relative to RIPK1 ligands22, we used a RIP1 kinase 
homology model including its activation loop to perform docking simulations in the aim to explore the asso-
ciation modes of 6E11 compound to RIPK1. Docking calculations were performed by using VINA standard 
protocol (YASARA, global docking, 1000 runs theoretical complexes computed). Clustering was achieved 
through Jarvis-Patrick method as implemented in the Gromacs suite. The best pose of the ligand towards the 
receptor (energy criteria) was submitted to a 60 ns molecular dynamics (MD) simulation in water to improve the 
model of 6E11-RIPK1 complex. As the ligand was stable during the MD trajectory, the final model was selected 
as the energy minimized most representative structure of the simulation (molecular frame at t = 37.570 ns). 
6E11-contacting residues were defined as surrounding amino acids given a 3.0 Å cut-off distance and pharma-
cophores were derived from a standard analysis by using the Ligand Scout program.
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In vitro “cold hypoxia/reoxygenation” assays. Human aortic endothelial cells (HAEC; Gibco, 
Waltham, MA, USA) were grown to 80% confluence, and then synchronized using FBS depleted media for 16 h. 
For hypothermia/hypoxia, cells were washed twice with PBS then incubated in University of Wisconsin (UW) 
solution in 95%N2/5%CO2 atmosphere at 4 °C for 24 h. Increasing concentrations of 6E11, 8A03, Nec-1 and 
Nec-1s were added in cell medium at various steps: hypoxia; hypoxia and reoxygenation; and only during reoxy-
genation. Controls are cells not subjected to this protocol and are continuously oxygenated for the same time in 
PBS supplemented with 2% of FBS. Cell viability was evaluated by XTT test (Sigma-Aldrich, St Quentin-Fallavier, 
France).
Statistical analyses. Data from a minimum of two experiments were expressed as means ± range; ± SD 
or ± SEM. Statistical analyses were done by ANOVA, Tukey’s Multiple Comparison Test and Student’s t-test 
for two groups of data, and significance levels used are *P < 0.05, **P < 0.01, ***P < 0.001 by using GraphPad 
Prism6 software (GraphPad Software, San Diego, CA, USA).
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